Chemical Biology and Drug Design

SEPTEMBER 6, 2023

Matrine inhibits TNBC cell proliferation, migration and invasion, promotes apoptosis, and suppresses tumor growth through down-regulation of HN1 expression. Abstract The treatment of triple-negative breast cancer (TNBC) cannot meet medical needs, and it is urgent to find new drugs for intervention.

Regulations 100

Regulations Protein Expression Treatment Drugs 100

Drug Discovery World

JUNE 14, 2023

The recent clinical trial for metastatic breast cancer patients (DESTINY-Breast04) found that a treatment traditionally used for HER2 positive patients was also effective in patients considered HER2 negative. It used the current CAP/ASCO testing algorithm for HER2 protein expression levels.

Protein Expression 130

Protein Expression Clinical Trials Trials Laboratories 130

Drug Discovery World

JUNE 23, 2023

The Food and Drug Administration (FDA) has granted accelerated approval to Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus (AAV) based gene therapy for the treatment of DMD. The FDA’s accelerated approval is based on an increase in Elevidys micro-dystrophin protein expression in skeletal muscle.

FDA Approval 243

FDA Approval Therapies FDA Protein Expression 243

Drug Discovery World

FEBRUARY 28, 2023

With only 10% of these conditions indicated for an approved therapy, there is a sizable opportunity for scientists and companies to develop treatments for patients with no other options to turn to. The post Unlocking the potential of mRNA for the future treatment of rare diseases appeared first on Drug Discovery World (DDW).

Disease 130

Disease Treatment Vaccine DNA 130

Chemical Biology and Drug Design

DECEMBER 20, 2023

As such, triptolide is expected to be a potential drug for colorectal cancer treatment. The protein expression levels of nuclear factor-erythroid 2-related factor 2 (Nrf2), matrix metalloproteinase (MMP)-2, and MMP-9 were detected by western blotting. Its mechanism of action may be related to the inhibition of Nrf2 signaling.

Protein Expression 100

Protein Expression Treatment Drugs Research 100

Chemical Biology and Drug Design

AUGUST 2, 2023

Group 1: the control group, Group 2: STZ-induced diabetes+insulin treatment group, Group 3: STZ-induced diabetes+linagliptin treatment group, Group 4: STZ-induced diabetes+linagliptin+insulin treatment group, Group 5: STZ-induced diabetes+TUDCA treatment group, Group 6: STZ-induced diabetes+TUDCA+insulin treatment group.

Protein Expression 100

Protein Expression Therapies Treatment Research 100

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

Chemical Biology and Drug Design

FEBRUARY 15, 2024

However, the DE disease pathogenesis remains unclear, thereby affecting its clinical treatment. RT-qPCR and western blotting were used to test the mRNA and protein expression levels of IL-17 and retinoid-related orphan receptor-γt (RORγt). PGE2 was highly expressed in the DE mouse model.

Disease 100

Disease Protein Expression Regulations Treatment 100

Chemical Biology and Drug Design

JUNE 8, 2023

Compared with the control group (0 mM SAS), the proliferation of TE-1 cells was significantly inhibited by different concentrations of SAS for different time lengths, and 4 mM SAS treatment for 48 h could obtain the maximum inhibition rate (53.9%).

Protein Expression 100

Protein Expression Treatment Research 100

Chemical Biology and Drug Design

SEPTEMBER 25, 2023

Vinp treatment promotes Wnt proteins to connect the receptors complex on the cell membrane (consisting of FZD and LRP5/6), and then β-catenin is subsequently dissociated from the complex and translocated to the nucleus, activating transcription of downstream target genes. The mechanism diagram of Vinp on PD.

Disease 100

Disease Protein Expression Treatment Research 100

Chemical Biology and Drug Design

SEPTEMBER 24, 2023

This finding provides new ideas for the development of drug targets for the treatment of ischemic stroke. This research is powered to probe whether the molecular mechanism of JAS for IS treatment is coupled with microglia polarization. The polarization of microglia affects IS process.

Regulations 100

Regulations Protein Expression Treatment Research 100

Drug Discovery World

SEPTEMBER 8, 2022

Pleco claims that its novel Plecoid therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell, thereby improving the effectiveness of existing chemotherapy. cases per 100,000 population).

Protein Expression 130

Protein Expression Drugs Government FDA 130

Chemical Biology and Drug Design

MARCH 4, 2024

Abstract Anlotinib is used for the treatment of advanced non-small cell lung cancer; however, the emergence of drug resistance limits its clinical application. The expression of miR-181a-3p was inhibited; however, SHQ1 expression was increased by β-sitosterol treatment of A549/anlotinib cells.

Protein Expression 100

Protein Expression Regulations Treatment Drugs 100

Chemical Biology and Drug Design

AUGUST 9, 2023

A label-free proteomics technology was employed to investigate alterations in protein expression in LoVo cells treated with plumbagin. The LC-MS/MS proteomics assay revealed 78 proteins that were differentially expressed upon treatment with plumbagin.

Bioinformatics 100

Bioinformatics Protein Expression Treatment Research 100

Chemical Biology and Drug Design

DECEMBER 6, 2023

However, the pharmacodynamic mechanism and molecular target of SP-FC in the treatment of HS are still unclear. Therefore, this study is intended to explore the mechanism and target of SP-FC in the treatment of HS through network pharmacology combined with in vitro cell and molecular biology experiments.

Molecular Biology 100

Molecular Biology Protein Expression Treatment Regulations 100

Chemical Biology and Drug Design

AUGUST 23, 2023

The protein expressions were detected via western blot. The THS showed increased inflammation response proteins, mitochondria-dependent apoptosis proteins, and had a compensation effect on the Akt pathway. Ligustrazine at doses of 100 and 1000 μg/mL was administrated in Kupffer cells isolated from THS rats.

Protein Expression 100

Protein Expression Protein Production Production Treatment 100

Chemical Biology and Drug Design

AUGUST 21, 2023

Further, the study detected the effect of SA on cell apoptosis, lipid peroxidation, Fe 2+ level, and ferroptosis-related proteins expression. Finally, the effect of HMGB1 expression on SA in H/R stimulation was studied. Such effects of SA on H/R-induced cells were rescued by HMGB1 overexpression.

Protein Expression 100

Protein Expression Treatment Research 100

Chemical Biology and Drug Design

SEPTEMBER 21, 2023

Concretely, CPT-11 induced delayed diarrhea rat model and intestinal epithelial cell (IEC)-6 cell injury model with Baicalein treatment as needed. Colonic pathological changes were analyzed by hematoxylin–eosin staining, and inflammatory factor expressions in serum were determined by enzyme-linked immunosorbent assay.

Protein Expression 100

Protein Expression Treatment Research 100

Chemical Biology and Drug Design

DECEMBER 8, 2023

ELANE knockdown offset CAMP silencing-mediated inhibition of viability and promotion of inflammatory factors and pyroptosis-related protein expression in LPS/ATP/BoNT/A-treated rat DRG neurons. Conclusively, BoNT/A alleviates rat DRG neuron pyroptosis during PHN by upregulating CAMP to inhibit ELANE.

Protein Expression 100

Protein Expression Treatment Research 100

Drug Discovery World

SEPTEMBER 13, 2023

A Translational Psychiatry publication indicates that SARS-CoV-2 infection, even when unnoticed or asymptomatic, can have an influence on the activation of the Human Endogenous Retrovirus W (W-ENV) protein in psychotic patients, in a context of innate immune inflammation.

Protein Expression 130

Protein Expression Clinical Trials Hospitals Trials 130

Drug Discovery World

MAY 2, 2023

Today, scientists leverage this defence mechanism to learn more about the genomic alterations in diseased states as well as the impact of drug treatments on the human genome. These modifications lead to alterations in the function of the proteins expressed by these genes, manifesting in cellular processes dependent on those proteins.

DNA 130

DNA RNA Protein Expression Drugs 130

Drug Discovery World

JANUARY 23, 2023

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment. DS: How will your work ultimately impact disease treatment?

RNA 246

RNA Engineering Therapies Disease 246

Drug Discovery World

NOVEMBER 8, 2023

Helmut Salih, MD, Professor for Translational Immunology, Medical Director, Clinical Collaboration Unit Translational Immunology, University Hospital Tuebingen and DKFZ Heidelberg, Germany; Co-Founder, TWYCE GmbH, on: ‘An optimised IgG-Based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers’. Claes Gustafsson, Ph.D,

Engineering 162

Engineering Protein Expression Therapies Science 162

ASPET

OCTOBER 20, 2023

Western blotting was utilized for protein expression and epigenetic studies utilized chromatin immunoprecipitation methods. Furthermore, KET restored acetylated histone occupancy at the Bdnf promoter IV and induced BDNF protein expression in DFP rats. mg/kg s.c., At 6-m following DFP exposure, KET (10 mg/kg, i.p.)

Protein Expression 40

Protein Expression Clinical Trials Therapies FDA 40

Drug Discovery World

SEPTEMBER 5, 2022

Modulations in protein expression levels or the presence of dysfunctional proteins observed in individuals with specific mutations act as biomarkers in selecting patients for targeted therapies. . When selecting patients for therapy, we currently look at variants that directly affect protein expression or function.

Drug Development 130

Drug Development Protein Expression Drugs Therapies 130

Drug Discovery World

APRIL 30, 2024

The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market. The mice given the treatment survived for over three months.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

ASPET

AUGUST 31, 2023

Proteomic analysis with the use of the Q Exactive HF mass spectrometer, combined with biostatistic tests, performed on UVA-irradiated keratinocytes indicated enhanced and lowered expression of 186 and 160 proteins, respectively.

Protein Expression 40

Protein Expression Treatment 40

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. Vallabh soon found out that she inherited the same disease-causing mutation in the prion protein gene. Credit: Neumann EN, Bertozzi TM, et al.

Disease 137

Disease Therapies Engineering Clinical Trials 137

The Pharma Data

NOVEMBER 26, 2020

(NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A.,

Disease 52

Disease Treatment Clinical Trials FDA 52

The Pharma Data

MARCH 26, 2021

If approved, Tecentriq could offer people with a specific type of lung cancer a chemotherapy-free option in the first-line treatment setting. We remain committed to providing effective and tailored lung cancer treatment options, and this announcement is an important step toward this goal.”. months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89;

Treatment 52

Treatment Protein Expression Therapies Immune Response 52

Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

Therapies 58

Therapies RNA Protein Expression DNA 58

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Target Review

OCTOBER 6, 2023

This interview explores how CoRegen’s innovative techniques are not only transforming cancer treatment but also hold promise for a wide range of medical applications, all while minimising the side effects often associated with traditional therapies.

Small Molecule 110

Small Molecule Engineering Protein Expression Regulations 110

The Pharma Data

SEPTEMBER 10, 2020

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study. 97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world data.

Treatment 52

Treatment FDA Approval Disease Clinical Trials 52

Drug Target Review

JANUARY 26, 2024

Dr Freimuth stated: “These infectivity assays showed that the human ACE2 protein expressed on these mouse cells is fully functional.” They also investigated the placement of ACE2 proteins onto nanoparticles for possible applications in rapid virus detection or infection treatment.

Production 113

Production DNA Virus Protein Expression 113

The Pharma Data

JANUARY 15, 2021

for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. .–(BUSINESS WIRE) January 15, 2021 — Daiichi Sankyo Company, Ltd. In the U.S., Sammons Cancer Center and the W.W. Caruth, Jr.

Treatment 52

Treatment Trials Disease Therapies 52

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52